<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245319</url>
  </required_header>
  <id_info>
    <org_study_id>Acitretin in vitiligo</org_study_id>
    <nct_id>NCT04245319</nct_id>
  </id_info>
  <brief_title>Combined Effect of Acitretin and Narrow Band Ultraviolet B on Vitiligo Repigmentation</brief_title>
  <official_title>Assessment of the Combined Effect of Acitretin and Narrow Band Ultraviolet B (Nb-UVB) on the Clinical Repigmentation and on the Expression of E-cadherins in Vitiligo Lesions in Comparison to Narrow Band UVB Alone. A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since abnormal keratinocyte (KC) proliferation and differentiation as well as defective E&#xD;
      cadherin expression were reported in vitiligo lesions, the investigators set to study the&#xD;
      potential efficacy of combining Retinoids, which are known to improve KC proliferation and&#xD;
      differentiation and increase the expression of adhesion molecules, with narrowband UVB in the&#xD;
      treatment of vitiligo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      • Twenty patients with generalized vitiligo will be included in this study.&#xD;
&#xD;
      All patients will be subjected to:&#xD;
&#xD;
        -  Clinical evaluation:&#xD;
&#xD;
        -  An informed written consent.&#xD;
&#xD;
        -  History taking include age, previous treatment, disease activity&#xD;
&#xD;
        -  Clinical examination including Vitiligo Area Scoring Index (VASI) and Vitiligo Disease&#xD;
           Activity Score (VIDA)&#xD;
&#xD;
        -  Photography (before starting the treatment and every 2 weeks till the end of the study)&#xD;
&#xD;
      Laboratory evaluation:&#xD;
&#xD;
        -  2 mm punch skin biopsies will be taken from vitiligo patients, 1 from lesional and the&#xD;
           other from perilesional skin before treatment.&#xD;
&#xD;
        -  The patients will be randomly assigned to two groups:&#xD;
&#xD;
      Group A: patients will receive three NB-UVB sessions per week for 48 sessions. Group B:&#xD;
      patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin&#xD;
      in a dose of 0.3mg/kg/day daily.&#xD;
&#xD;
        -  Controls: 20 individuals age and sex matched will be biopsied from the skin of their&#xD;
           abdominoplasty surgery.&#xD;
&#xD;
        -  Another two 2 mm punch skin biopsies will be taken from lesional and perilesional skin&#xD;
           at the onset of repigmentation if repigmentation starts before completion of the 48&#xD;
           treatment session or after completion of the treatment period if repigmentation does not&#xD;
           occur.&#xD;
&#xD;
        -  .All biopsies from patients and controls will be stained Immunohistochemically by anti-E&#xD;
           cadherin antibody.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups Group A: patients will receive three NB-UVB sessions per week for 48 sessions. Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3 mg/kg/day daily.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determining whether addition of acitretin is beneficial for vitiligo patients or not using Vitiligo Area Scoring Index</measure>
    <time_frame>4-5 months</time_frame>
    <description>The number of patients who will achieve 100%, 75% and 50% repigmentation of vitiligo lesions will be compared between group A (nbUVB) and group B (nbUVB+ acitretin) after 48 nbUVB sessions. The comparison of the 2 groups will be assessed using Vitiligo Area Scoring Index (VASI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determining whether addition of acitretin is beneficial for vitiligo patients or not using Vitiligo Disease Activity Score.</measure>
    <time_frame>4-5 months</time_frame>
    <description>The number of patients who will achieve 100%, 75% and 50% repigmentation of vitiligo lesions will be compared between group A (nbUVB) and group B (nbUVB+ acitretin) after 48 nbUVB sessions. The comparison of the 2 groups will be assessed using Vitiligo Disease Activity Score (VIDA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hyperlipidemias</condition>
  <condition>Xerosis</condition>
  <condition>Depression</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>NbUVB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Group A: patients will receive three NB-UVB sessions per week for 48 sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined nbUVB and Acitretin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3mg/kg/day daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin</intervention_name>
    <description>The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed</description>
    <arm_group_label>Combined nbUVB and Acitretin</arm_group_label>
    <other_name>Acitretin 25Mg Cap</other_name>
    <other_name>Acitretin 10Mg Cap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Narrow band ultraviolet B</intervention_name>
    <description>Patients receive nbUVB session 3 times per week</description>
    <arm_group_label>Combined nbUVB and Acitretin</arm_group_label>
    <arm_group_label>NbUVB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with generalized non-segmental vitiligo (25%-75%)&#xD;
&#xD;
          -  Males, postmenopausal females and premenopausal females not planning to get pregnant&#xD;
             during the period of treatment and after 2 years from the end of treatment.&#xD;
&#xD;
          -  Age more than 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children ˂ 18 years old&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Premenopausal females planning to get pregnant within the period of treatment or&#xD;
             within 2 years after.&#xD;
&#xD;
          -  Patients receiving treatment for vitiligo within the past 2 months.&#xD;
&#xD;
          -  Patients with abnormal liver profile&#xD;
&#xD;
          -  Patients with abnormal lipid profile&#xD;
&#xD;
          -  Patients with associated photosensitive disorders&#xD;
&#xD;
          -  Patients having associated skin diseases other than vitiligo&#xD;
&#xD;
          -  Cataract and aphakia&#xD;
&#xD;
          -  High cumulative dose from previous sessions of narrowband ˃ 200-300 session&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Noha A. Saleh, M.Sc</last_name>
    <phone>+201222177210</phone>
    <email>noushy2938@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11956</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Shahira Ramadan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Vitiligo</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

